Ramadori, Giuliano

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","Journal of Cellular and Molecular Medicine"],["dc.bibliographiccitation.lastpage","9"],["dc.contributor.author","Malik, Gesa"],["dc.contributor.author","Wilting, Jörg"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Ramadori, Giuliano"],["dc.contributor.author","Malik, Ihtzaz Ahmed"],["dc.date.accessioned","2019-07-09T11:50:04Z"],["dc.date.available","2019-07-09T11:50:04Z"],["dc.date.issued","2019"],["dc.description.abstract","The mechanisms of radiation-induced liver damage are poorly understood. We investigated if tumour necrosis factor (TNF)-α acts synergistically with irradiation, and how its activity is influenced by platelet endothelial cell adhesion molecule-1 (PECAM-1). We studied murine models of selective single-dose (25 Gy) liver irradiation with and without TNF-α application (2 μg/mouse; i.p.). In serum of wild-type (wt)-mice, irradiation induced a mild increase in hepatic damage marker aspartate aminotransferase (AST) in comparison to sham-irradiated controls. AST levels further increased in mice treated with both irradiation and TNF-α. Accordingly, elevated numbers of leucocytes and increased expression of the macrophage marker CD68 were observed in the liver of these mice. In parallel to hepatic damage, a consecutive decrease in expression of hepatic PECAM-1 was found in mice that received radiation or TNF-α treatment alone. The combination of radiation and TNF-α induced an additional significant decline of PECAM-1. Furthermore, increased expression of hepatic lipocalin-2 (LCN-2), a hepatoprotective protein, was detected at mRNA and protein levels after irradiation or TNF-α treatment alone and the combination of both. Signal transducer and activator of transcription-3 (STAT-3) seems to be involved in the signalling cascade. To study the involvement of PECAM-1 in hepatic damage more deeply, the liver of both wt- and PECAM-1-knock-out-mice were selectively irradiated (25 Gy). Thereby, ko-mice showed higher liver damage as revealed by elevated AST levels, but also increased hepatoprotective LCN-2 expression. Our studies show that TNF-α has a pivotal role in radiation-induced hepatic damage. It acts in concert with irradiation and its activity is modulated by PECAM-1, which mediates pro- and anti-inflammatory signalling."],["dc.identifier.doi","10.1111/jcmm.14224"],["dc.identifier.pmid","30761739"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15851"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59695"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1582-4934"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","PECAM-1 modulates liver damage induced by synergistic effects of TNF-α and irradiation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","7347"],["dc.bibliographiccitation.issue","41"],["dc.bibliographiccitation.journal","World Journal of Gastroenterology"],["dc.bibliographiccitation.lastpage","7358"],["dc.bibliographiccitation.volume","23"],["dc.contributor.author","Malik, Ihtzaz Ahmed"],["dc.contributor.author","Wilting, Jörg"],["dc.contributor.author","Ramadori, Giuliano"],["dc.contributor.author","Naz, Naila"],["dc.date.accessioned","2019-07-09T11:44:36Z"],["dc.date.available","2019-07-09T11:44:36Z"],["dc.date.issued","2017"],["dc.description.abstract","AIM To studied iron metabolism in liver, spleen, and serum after acute liver-damage, in relation to surrogate markers for liver-damage and repair. METHODS Rats received intraperitoneal injection of the hepatotoxin thioacetamide (TAA), and were sacrificed regularly between 1 and 96 h thereafter. Serum levels of transaminases and iron were measured using conventional laboratory assays. Liver tissue was used for conventional histology, immunohistology, and iron staining. The expression of acute-phase cytokines, ferritin light chain (FTL), and ferritin heavy chain (FTH) was investigated in the liver by qRT-PCR. Western blotting was used to investigate FTL and FTH in liver tissue and serum. Liver and spleen tissue was also used to determine iron concentrations. RESULTS After a short initial decrease, iron serum concentrations increased in parallel with serum transaminase (aspartate aminotransferase and alanine aminotransferase) levels, which reached a maximum at 48 h, and decreased thereafter. Similarly, after 48 h a significant increase in FTL, and after 72h in FTH was detected in serum. While earliest morphological signs of inflammation in liver were visible after 6 h, increased expression of the two acute-phase cytokines IFN-γ (1h) and IL-1β (3h) was detectable earlier, with maximum values after 12-24 h. Iron concentrations in liver tissue increased steadily between 1 h and 48 h, and remained high at 96 h. In contrast, spleen iron concentrations remained unchanged until 48 h, and increased mildly thereafter (96 h). Although tissue iron staining was negative, hepatic FTL and FTH protein levels were strongly elevated. Our results reveal effects on hepatic iron concentrations after direct liver injury by TAA. The increase of liver iron concentrations may be due to the uptake of a significant proportion of the metal by healthy hepatocytes, and only to a minor extent by macrophages, as spleen iron concentrations do not increase in parallel. The temporary increase of iron, FTH and transaminases in serum is obviously due to their release by damaged hepatocytes. CONCLUSION Increased liver iron levels may be the consequence of hepatocyte damage. Iron released into serum by damaged hepatocytes is obviously transported back and stored via ferritins."],["dc.identifier.doi","10.3748/wjg.v23.i41.7347"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14835"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59046"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2219-2840"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.subject.ddc","610"],["dc.title","Reabsorption of iron into acutely damaged rat liver: A role for ferritins"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","327"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","European journal of gastroenterology & hepatology"],["dc.bibliographiccitation.lastpage","334"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Cameron, Silke"],["dc.contributor.author","Haller, Florian"],["dc.contributor.author","Dudas, Joszef"],["dc.contributor.author","Moriconi, Federico"],["dc.contributor.author","Gunawan, Bastian"],["dc.contributor.author","Armbrust, Thomas"],["dc.contributor.author","Langer, Claus"],["dc.contributor.author","Füzesi, Laszlo"],["dc.contributor.author","Ramadori, Giuliano"],["dc.date.accessioned","2011-05-13T14:17:12Z"],["dc.date.accessioned","2021-10-27T13:10:51Z"],["dc.date.available","2011-05-13T14:17:12Z"],["dc.date.available","2021-10-27T13:10:51Z"],["dc.date.issued","2008"],["dc.description.abstract","INTRODUCTION: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. They are regarded as having relatively uniform histology, although their potential for malignant behavior varies. Despite a strong promoting role of tumor-infiltrating innate immune cells in neoplastic progression, the presence of immune cells in GISTs has not yet been studied. METHODS: A total of 47 untreated, c-kit-positive primary GISTs were immunohistochemically analyzed to distinguish histiocytic and dendritic cells (DCs) (KIM-1P, fascin, and CD68) from cells of lymphoplasmacellular origin (CD3, CD20, and CD56). Furthermore, the gene expression of proinflammatory cytokines was characterized by real-time, reverse transcription-PCR analysis of total RNA extracted from frozen tissue samples. RESULTS: KIM-1P+ cells were the dominant immune cells (851+/-295 cells/mm2) and were scattered among the tumor cells. Most of the KIM-1P+ cells showed cellular projections characteristic of DCs. Fascin positivity identified a subgroup of DCs. In comparison to KIM-1P+ cells, there were significantly fewer CD68+ macrophages (196+/-217 cells/mm2). CD3+ T cells were the dominant lymphocytes (201+/-331 cells/mm2), whereas B cells (60+/-126 cells/mm2) were few. On transcriptional level, a concomitant gene expression of cytokines for the classical acute phase cytokines TNF-alpha and IL-6 was missing, thus supporting the rather innate status of immune cells. CONCLUSION: GISTs contain, beside T lymphocytes, a high number of monocyte-derived cells, which we suggest are, at least in part, immature DCs. Together with the lack of gene expression of inflammatory cytokines in tumor tissue our results point to a possible 'symbiotic relationship' between the tumor and the local immune cells."],["dc.identifier.doi","10.1097/MEG.0b013e3282f3a403"],["dc.identifier.isi","000257628200013"],["dc.identifier.pmid","18334877"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6331"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/91538"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","0954-691X"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.subject.mesh","Adult"],["dc.subject.mesh","Aged"],["dc.subject.mesh","Aged, 80 and over"],["dc.subject.mesh","Antigens, CD"],["dc.subject.mesh","Antigens, CD3"],["dc.subject.mesh","Antigens, Differentiation, Myelomonocytic"],["dc.subject.mesh","Cell Communication"],["dc.subject.mesh","Cell Transformation, Neoplastic"],["dc.subject.mesh","Cytokines"],["dc.subject.mesh","Dendritic Cells"],["dc.subject.mesh","Female"],["dc.subject.mesh","Gastrointestinal Stromal Tumors"],["dc.subject.mesh","Humans"],["dc.subject.mesh","Male"],["dc.subject.mesh","Middle Aged"],["dc.subject.mesh","Phenotype"],["dc.subject.mesh","Proto-Oncogene Proteins c-kit"],["dc.subject.mesh","Stromal Cells"],["dc.title","Immune cells in primary gastrointestinal stromal tumors"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","BMC Comparative hepatology"],["dc.bibliographiccitation.lastpage","12"],["dc.bibliographiccitation.volume","5"],["dc.contributor.author","Meier, Volker"],["dc.contributor.author","Tron, Kyrylo"],["dc.contributor.author","Batusic, Danko"],["dc.contributor.author","Elmaouhoub, Abderrahim"],["dc.contributor.author","Ramadori, Giuliano"],["dc.date.accessioned","2019-07-09T11:41:48Z"],["dc.date.available","2019-07-09T11:41:48Z"],["dc.date.issued","2006"],["dc.description.abstract","Background: Alpha-fetoprotein (AFP) expression can resume in the adult liver under pathophysiological conditions. Orphan nuclear receptors were supposed to regulate AFP gene expression, in vitro. We were interested to study the expression of AFP and orphan nuclear receptors, in vivo. Results: The expression of AFP gene and orphan nuclear receptors in the liver was examined in different rat models: (a) fetal liver (b) liver regeneration [partial hepatectomy (PH) with and without 2-acetyl-aminofluren treatment (2-AAF)], (c) acute liver damage [treatment with CCl4] and (d) acute phase reaction treatment with turpentine oil]. After PH of 2-AAF treated rats, clusters of AFP positive cells occurred in the periportal region. In the Northern blot analysis, a positive hybridization signal for the full-length AFP-RNA was observed only in liver samples from 2-AAF treated rats after PH. In real-time PCR analysis, the full-length AFP-RNA was highly up regulated in the fetal liver (maximum at day 14: 21,500 fold); after PH of 2-AAF treated rats, the full-length AFPRNA was also up regulated up to 400 fold (day 7 after PH). The orphan nuclear receptors were down regulated at nearly each time points in all models, also at time point of up regulation of the AFP gene..."],["dc.identifier.doi","10.1186/1476-5926-5-2"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/1241"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58515"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","616"],["dc.subject.ddc","610"],["dc.title","Expression of AFP and Rev-Erb A/Rev-Erb B and N-CoR in fetal rat liver, liver injury and liver regeneration"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","10"],["dc.bibliographiccitation.journal","BMC Gastroenterology"],["dc.bibliographiccitation.volume","7"],["dc.contributor.author","Scharf, Jens-Gerd"],["dc.contributor.author","Ramadori, Giuliano"],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Mueller, Annegret"],["dc.date.accessioned","2018-11-07T11:04:05Z"],["dc.date.available","2018-11-07T11:04:05Z"],["dc.date.issued","2007"],["dc.description.abstract","Background: While the mortality of esophageal surgery has decreased due to technological advancements, there is still a complication rate of about 30%. One of the main complications is the anastomotic leakage associated with a significant rate of morbidity and mortality. To close the leakage the efficacy of self-expanding stents (SES) has been shown in different studies. However, the high rate of stent migration limits the use of commercial available stents. In our case we were faced with the problem that the diameter of all available stents was too small to attach tightly to the mucosal wall of the esophagogastric anastomosis. Case presentation: We used, for the first time to our knowledge, a metal stent designed for colorectal application in an extensive anastomotic leak after esophageal resection in a patient with an esophageal cancer. After primary surgery with subtotal esohagectomy the anastomotic leak was stented endoscopically with a Polyflex self-expanding covered plastic stent after no response to intensive conventional management. Even though the stent was placed correctly, the diameter of the Polyflex stent was too small to attach onto the wall of the esophagogastric anastomosis. Again surgery was performed with a thoracal resection of the esophageal remnant and a hand made anastomosis. Unfortunately, again an anastomotic leak was detected soon after. To close the leak we decided to use a covered colorectal stent (Hanarostent) with an inner diameter of 30 mm. Sixteen weeks later the stent was extracted and complete mucosal healing of the esophageal leak was observed. Conclusion: The stent implantation with a large wide diameter offers a good chance to close more extensive leaks and prevent stent migration."],["dc.identifier.doi","10.1186/1471-230X-7-10"],["dc.identifier.fs","52491"],["dc.identifier.isi","000245455700001"],["dc.identifier.pmid","17367525"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/1268"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/51754"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1471-230X"],["dc.rights","Goescholar"],["dc.rights.access","openAccess"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.subject.ddc","616"],["dc.title","Implantation of a colorectal stent as a therapeutic approach in the treatment of esophageal leakage"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","43"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","HPB surgery"],["dc.bibliographiccitation.lastpage","49"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Samel, S."],["dc.contributor.author","Horst, F."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Brinck, U."],["dc.contributor.author","Schwörer, H."],["dc.contributor.author","Ramadori, G."],["dc.contributor.author","Oestmann, J.-W."],["dc.date.accessioned","2019-07-09T11:52:32Z"],["dc.date.available","2019-07-09T11:52:32Z"],["dc.date.issued","1998"],["dc.description.abstract","The rare neoplastic cystic adenomas of the pancreas form two groups of tumors: macrocystic mucinous and microcystic serous adenomas. Both entities show specific radiologic and histologic features. Several recent case reports, however, suggest some diversity within the group of microcystic serous adenomas. We present the case of a young man operated because of epigastric pain for 12 months and a palpable microcystic tumor of the pancreatic head. Multiple cysts communicating with branches of the pancreatic duct in an alveolar-like pattern were demonstrated on endoscopic retrograde cholangiopancreatography. Histologic examination of the specimen confirmed the diagnosis of a serous adenoma of the pancreas. The tumor morphology in this case may suggest a ductal origin of microcystic serous adenomas."],["dc.identifier.doi","10.1155/1998/29353"],["dc.identifier.fs","1136"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/4466"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60212"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1607-8462"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Serous Adenoma of the Pancreas With Multiple Microcysts Communicating With the Pancreatic Duct"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","191"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Journal of Gastrointestinal Cancer"],["dc.bibliographiccitation.lastpage","194"],["dc.bibliographiccitation.volume","42"],["dc.contributor.author","Thiel, David"],["dc.contributor.author","Ramadori, Guiliano"],["dc.date.accessioned","2019-07-09T11:53:14Z"],["dc.date.available","2019-07-09T11:53:14Z"],["dc.date.issued","2010"],["dc.description.abstract","Hepatocellular carcinoma (HCC) is a major cause of cancer worldwide. The vast majority of cases occur in individuals with a chronic HBV or HCV infection. In addition, a number of metabolic diseases of the liver are associated with the development of HCC.The mechanisms responsible for the progression of the metabolic liver disease and HCC differ from those associated with viral liver disease.The purpose of this report is to describe the mechanisms responsible for the disease progression and HCC in case of metabolic liver disease. A secondary goal is to identify the frequency of HCC development in the disorders described."],["dc.identifier.doi","10.1007/s12029-010-9195-3"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/7178"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60376"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","Springer"],["dc.publisher.place","Boston"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Non-Viral Causes of Hepatocellular Carcinoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","759581"],["dc.bibliographiccitation.firstpage","8"],["dc.bibliographiccitation.journal","Journal of Transplantation"],["dc.bibliographiccitation.volume","2009"],["dc.contributor.author","Goralczyk, Armin D."],["dc.contributor.author","Obed, Aiman"],["dc.contributor.author","Schnitzbauer, Andreas"],["dc.contributor.author","Doenecke, Axel"],["dc.contributor.author","Tsui, Tung Yu"],["dc.contributor.author","Scherer, Marcus N."],["dc.contributor.author","Ramadori, Giuliano"],["dc.contributor.author","Lorf, Thomas"],["dc.date.accessioned","2019-07-09T11:52:46Z"],["dc.date.available","2019-07-09T11:52:46Z"],["dc.date.issued","2009"],["dc.description.abstract","Adult living donor liver transplantations (ALDLTs) across the ABO blood group barrier have been reported in Asia, North Americas, and Europe, but not yet in Germany. Several strategies have been established to overcome the detrimental effects that are attached with such a disparity between donor and host, but no gold standard has yet emerged. Here, we present the first experiences with three ABO-incompatible adult living donor liver transplantations in Germany applying different immunosuppressive strategies. Four patient-donor couples were considered for ABO-incompatible ALDLT. In these patients, resident ABO blood group antibodies (isoagglutinins) were depleted by plasmapheresis or immunoadsorption and replenishment was inhibited by splenectomy and/or B-cell-targeted immunosuppression. Despite different treatments ALDLT could safely be performed in three patients and all patients had good initial graft function without signs for antibody-mediated rejection (AMR). Two patients had long-term graft survival with stable graft function. We thus propose the feasibility of ABO-incompatible ALDLT with these protocols and advocate further expansion of ABO incompatible ALDLT in multicenter trials to improve efficacy and safety."],["dc.identifier.doi","10.1155/2009/759581"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/5906"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60268"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Adult Living Donor Liver Transplantation with ABO-Incompatible Grafts: A German Single Center Experience"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","257"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Cancer"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Ramadori, Giuliano"],["dc.contributor.author","Bosio, Patrizia"],["dc.contributor.author","Moriconi, Federico"],["dc.contributor.author","Malik, Ihtzaz A."],["dc.date.accessioned","2019-07-09T11:45:17Z"],["dc.date.available","2019-07-09T11:45:17Z"],["dc.date.issued","2018"],["dc.description.abstract","BACKGROUND: After orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC), recurrent HCC mostly develops within 2 years. All cases of de novo HCC described so far occurred later than 2 years after OLT. Prevention of post-transplantation HCC has usually been tried to achieve by curing or controlling recurrent liver disease. This has been rationale for treatment with interferon (IFN)/ribavirin of HCV-recurrence in patients after OLT, transplanted for advanced HCV-induced liver disease and/or HCC. The availability of new and more efficient drugs has improved chances also for previously difficult-to-treat HCV-positive patients. CASE PRESENTATION: A 75 year-old male patient who had undergone OLT for decompensated HCV-cirrhosis in 2009, and bilio-digestive surgery in 2011 under tracrolimus (0.5 mg/day) and prednisone (5 mg/day) immunosuppressive therapy, started to receive antiviral treatment for recurrent HCV-infection of graft with 200 mg/day ribavirin in combination with ledipasvir and sofosbuvir by the end of October 2015. Because of multiple side effects (anemia, asthenia, infections, and reduction of kidney functions - palliated by treatment with erythropoietin), treatment was stopped after 16 weeks. At the third control, a minimal increase in alpha-fetoprotein (AFP) serum level to 10 μg/L was measured 8 months after therapy, whereas both liver sonography and serum transaminases were normal. The patient's general condition; however, remained poor, and a magnetic resonance imaging (MRI) of abdomen was performed 2 months later. A nodule of 3 cm in diameter with a pseudocapsule was found centrally in the liver. The patient had to be hospitalized for recurrent infections of the lung, overt ascites and peritonitis. Rapid tumor growth (10 cm) was detected during last stay in hospital (April 2017), concomitant with a rise of AFP-serum levels to 91 μg/L. The family decided to take the patient home, and best supportive care was provided by a general practitioner, local nurses and the patient's dedicated wife until his death. CONCLUSION: Before treating OLT patients with HCV graft reinfection one should not only consider possible advantages of newly effective antiviral-therapies, but also life expectancy and possible side effects (difficult to manage at an outpatient service basis), including severe disadvantages such as the development of HCC."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2018"],["dc.identifier.doi","10.1186/s12885-018-4175-2"],["dc.identifier.pmid","29510685"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15129"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15090"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59200"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1471-2407"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","Case report: 8 years after liver transplantation: de novo hepatocellular carcinoma 8 months after HCV clearance through IFN-free antiviral therapy."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","154"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Case reports in oncology"],["dc.bibliographiccitation.lastpage","159"],["dc.bibliographiccitation.volume","3"],["dc.contributor.author","Ramadori, G."],["dc.contributor.author","Cameron, S."],["dc.contributor.author","Tschechne, B."],["dc.date.accessioned","2019-07-09T11:53:07Z"],["dc.date.available","2019-07-09T11:53:07Z"],["dc.date.issued","2010"],["dc.description.abstract","BACKGROUND: Second as well as higher-line therapies have a significant influence on progression-free and overall survival of metastatic colorectal cancer patients. However, treatment of late-stage disease remains suboptimal. Therefore, the introduction of new, effective and well-tolerated agents is of major importance. Case Reports: Here we describe the cases of 2 patients with metastatic KRAS wild-type colorectal cancer who received a fourth-line monotherapy with panitumumab after failure of 5-fluorouracil, irinotecan, oxaliplatin, and bevacizumab. RESULTS: Both patients achieved a partial remission, and for 11.5 and 18 months, respectively, they had a stable disease with initial reduction in the tumor marker carcinoembryonic antigen. Both patients reported a good tolerability of the treatment with improved quality of life (compared to receiving combined chemotherapy). CONCLUSION: Panitumumab monotherapy is an effective and well tolerated treatment of metastatic colorectal cancer in extensively pretreated KRAS wild-type patients. Our data have shown a response to panitumumab monotherapy for more than 11 months."],["dc.identifier.doi","10.1159/000312107"],["dc.identifier.fs","577121"],["dc.identifier.pmid","20740189"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6903"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60343"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1662-6575"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Long-Lasting Tumor Response in Patients with Panitumumab Monotherapy for Chemorefractory Metastatic Colorectal Carcinoma - A Report of Two Cases."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]